ALK21-025: Vivitrol's Cost and Treatment Outcomes Registry
VICTORY
VIvitrol's Cost and Treatment Outcomes RegistrY
1 other identifier
observational
403
1 country
31
Brief Summary
The objective of the VIVITROL Registry is to gather real world data on opioid dependence and to provide understanding of the health economics of opioid dependence.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2011
Typical duration for all trials
31 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2011
CompletedFirst Submitted
Initial submission to the registry
August 23, 2011
CompletedFirst Posted
Study publicly available on registry
August 24, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2013
CompletedNovember 16, 2018
November 1, 2018
2.2 years
August 23, 2011
November 15, 2018
Conditions
Keywords
Eligibility Criteria
The VIVITROL Registry will enroll patients who have been prescribed VIVITROL for the prevention of relapse to opioid dependence, following opioid detoxification.
You may qualify if:
- Patient is aged 18 years or older
- Patient is diagnosed with a current opioid dependence for which treatment with VIVITROL is being initiated
- Patient has provided written informed consent
- Patient is willing and able to provide the information to be collected via the registry's interviews and questionnaires
- Patient expects to be available for ongoing registry participation
You may not qualify if:
- Prior use of VIVITROL
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Alkermes, Inc.lead
Study Sites (31)
Assisted Recovery Centers of America
Phoenix, Arizona, 85014, United States
Arkansas Psychiatric Clinc
Little Rock, Arkansas, 72223, United States
Amy Solomon, MD
Ben Lomond, California, 95005, United States
Touchstone Medical Group
Clovis, California, 93611, United States
Kenneth C. Russ, MD
Palm Springs, California, 92262, United States
Tarzana Treatment Centers
Tarzana, California, 91356, United States
The NeuroBehavioral Institute of Colorado, PC
Lone Tree, Colorado, 80124, United States
Psychotherapy Services, Etc.
Groton, Connecticut, 06340, United States
Jacqueline Boutrouille, MD
Tamarac, Florida, 33321, United States
Alliance Clinical Research
Winter Park, Florida, 32792, United States
Atlanta Institute of Medicine and Research
Atlanta, Georgia, 30328, United States
PACT Atlanta
Decatur, Georgia, 30030, United States
Gosnold-Thorne Counseling Center
Centerville, Massachusetts, 02632, United States
Dr. Li's Clinic
Milford, Massachusetts, 01757, United States
Assisted Recovery Centers of America
St Louis, Missouri, 63109, United States
Dent Neurologic Institute
Amherst, New York, 14226, United States
Dr. Michael Sanders
Great Neck, New York, 11021, United States
Fakhouri Medical
Hopewell Junction, New York, 12533, United States
Parallax Center
New York, New York, 10016, United States
Healing Comfort Clinic
Corvallis, Oregon, 97330, United States
Jasper Health
Media, Pennsylvania, 19063, United States
Institute of Addiction Medicine
Plymouth Meeting, Pennsylvania, 19462, United States
Innovation Laboratory/PEARL
Johnson City, Tennessee, 37604, United States
Urschel Recovery Science Institute
Dallas, Texas, 75225, United States
Holiner Psychiatric Group
Dallas, Texas, 75230, United States
Lenae White, MD, PA
Dallas, Texas, 75231, United States
Utah Addiction Medicine & Counseling
Bountiful, Utah, 84010, United States
Adolescent and Family Health Center, PC
Midlothian, Virginia, 23114, United States
Chessen and Associates
Newport News, Virginia, 23606, United States
Creekside Center for Integrative Medicine
Bellevue, Washington, 98005, United States
Child and Adolescent Psychiatry
Bothell, Washington, 98011, United States
Related Publications (1)
Saxon AJ, Akerman SC, Liu CC, Sullivan MA, Silverman BL, Vocci FJ. Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry. Addiction. 2018 Aug;113(8):1477-1487. doi: 10.1111/add.14199. Epub 2018 Apr 1.
PMID: 29493836RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Alkermes Medical Director
Alkermes, Inc.
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 23, 2011
First Posted
August 24, 2011
Study Start
August 1, 2011
Primary Completion
October 1, 2013
Study Completion
October 1, 2013
Last Updated
November 16, 2018
Record last verified: 2018-11